Millions of Americans who rely on importing prescription medications from Canadian and other international pharmacies are facing a significant disruption starting October 22, 2026. New U.S. Customs and Border Protection (CBP) regulations, implemented in conjunction with the Food and Drug Administration (FDA), are poised to block nearly all personal prescription drug shipments from entering the United States. This change stems from a CBP rule published on June 24, 2026, which alters entry procedures for international mail, requiring additional information for government agencies and effectively closing the personal importation pathway that has existed for over 25 years.
The core of the issue is that the new policy will prohibit the entry of any medication that is commercially available in the United States, even if the U.S. version is significantly more expensive. Furthermore, if a foreign pharmacy specifically markets its products to Americans, its shipments will also be restricted. The Canadian International Pharmacy Association (CIPA) has assessed these new requirements and concluded that, without a policy change, the current delivery arrangements for most personal prescription orders to U.S. patients will no longer be viable. They warn that virtually all routine personal prescription orders mailed from licensed Canadian and international pharmacies will be unable to reach Americans.
A key player in this process, Zonos, which serves as the customs broker of record for most major international postal systems, will be prevented from acting as the importer of record for pharmaceutical products that are commercially available in the U.S. This, combined with the FDA's policy on imported medications under the new procedures, is expected to capture nearly the entire market for personal prescription orders supplied by licensed Canadian and international pharmacies to Americans. While the CBP rule does not explicitly ban Canadian pharmacy shipments, its changes to customs entry requirements and the FDA's existing admissibility rules will have a severe practical effect, potentially making it impractical for foreign pharmacies to serve U.S. customers.
Canadian federal officials were reportedly not consulted on the specifics of this U.S. plan. Past discussions focused on allowing American patients to legally import cheaper prescription drugs from Canada, which even saw some U.S. states, like Florida, pass laws to facilitate this. However, Canadian organizations like the Best Medicines Coalition and the Canadian Pharmacists Association have long raised concerns about the potential strain on Canada's drug supply if it were to also serve U.S. consumers, warning of possible shortages and disrupted access for Canadians. The current changes are a customs procedure adjustment, but their implications are expected to be a de facto ban on personal prescription imports.
